ArticleEClinicalMedicine2025
Feasibility and safety of remote robotic hepatectomy: a prospective single-arm study with MP1000 system in China.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical application of robotic telesurgery in the Brazilian public health system: a consecutive case series.Clinics (Sao Paulo, Brazil) · 2026Article
- Feasibility of robotic telesurgery over wired and private 5 G networks within Brazil's public health system (SUS): a pilot study.Clinics (Sao Paulo, Brazil) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Telesurgery has demonstrated many advantages in certain scenarios. However, given the high risks of liver resection, there have been no prospective studies to evaluate the safety and effectiveness of robotic remote liver resection. This study aimed to evaluate the safety and effectiveness of the MP1000 remote surgical system in robot-assisted remote liver resection using the first prospective single-arm cohort study. Methods: This study was approved by the Clinical Trial Ethics Committee of Huazhong University of Science and Technology ([2024] (324)) and registered at Chinese Clinical Trial Registry (ChiCTR2500097679). Six patients were continuously recruited from March 1 to April 18, 2025. After strict preoperative evaluation, robotic liver resection was performed using the MP1000 remote surgical system. The primary outcomes were the surgical success rate and the incidence of complications. The postoperative task load of surgeons was assessed using the NASA-TLX scale. Findings: The network connection of the remote system was smooth. All surgeries were successfully completed without conversion to open surgery or local robot-assisted surgery. Surgeons reported a relatively low workload. All patients recovered smoothly and were discharged. However, the second patient developed bacteremia within 30 days after surgery and was readmitted but recovered after antibiotic treatment. Interpretation: Robotic remote liver resection is a feasible and effective minimally invasive treatment modality that can provide high-quality medical services to areas with constrained medical resources. Nevertheless, further multi-center, large-scale randomized controlled trials are required to verify its effectiveness and safety. Funding: This work was supported by the Noncommunicable Chronic Diseases- National Science and Technology Major Project (2023ZD0502001), National Natural Science Foundation of China (82473040), Hubei Province Key Technology Breakthrough Project (2023BAA016-3), Tongji Hospital Clinical Research Fund (2024TJCR014).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.